Episurf Medical Q4: First steps for the US market - Redeye

Redeye notes a continuous customer base growth (+72%), and we are encouraged by the company’s FDA approval for its Episealer Patellofemoral System, marking its first steps on US soil. Sales were in line with our estimates, albeit still at low figures. OPEX came in 19% higher, though without any reason for concern going forward.

Länk till analysen i sin helhet: https://www.redeye.se/research/880863/episurf-medical-q4-first-steps-for-the-us-market?utm_source=finwire&utm_medium=RSS